Literature DB >> 18417261

The hematologic manifestations of the antiphospholipid syndrome.

Imad Uthman1, Bertrand Godeau, Ali Taher, Munther Khamashta.   

Abstract

Various hematological pathologies have been described in association with antiphospholipid syndrome (APS). Thrombocytopenia is frequently found in APS patients, its incidence has ranged from 22-42% in different series, it is usually moderate (>50x10(9)/L) without clinical manifestation and requires no intervention. A high percentage of patients with isolated idiopathic thrombocytopenic purpura have antiphospholipid antibodies, however the pathogenetic role and the clinical importance of these antibodies in this condition is still not clear. Other hematological manifestations reported in association with APS include: bone marrow necrosis, and various thrombotic microangiopathic syndromes such as: thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, HELLP (hemolysis, elevated liver enzymes, low platelet) syndrome, and catastrophic APS. A high index of suspicion is needed for the early recognition and treatment of these conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417261     DOI: 10.1016/j.blre.2008.03.005

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  14 in total

Review 1.  Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature.

Authors:  Sarthak Gupta; Robert Zivadinov; Deepa Ramasamy; Julian L Ambrus
Journal:  Clin Rheumatol       Date:  2013-11-26       Impact factor: 2.980

2.  Thrombotic renal and adrenal manifestations of primary antiphospholipid syndrome.

Authors:  Lama Bazzi; Ali T Taher; Khaled M Musallam; Zeinab Saleh; Karim Z Masrouha; Imad Uthman
Journal:  Rheumatol Int       Date:  2009-08-22       Impact factor: 2.631

3.  Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies.

Authors:  Wendy J Langeberg; W Marieke Schoonen; Melissa Eisen; Laurence Gamelin; Scott Stryker
Journal:  Int J Hematol       Date:  2016-03-24       Impact factor: 2.490

Review 4.  Clinical assessment and management of cytopenias in lupus patients.

Authors:  Alana B Levine; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

5.  Aspirin insensitive thrombophilia: transcript profiling of blood identifies platelet abnormalities and HLA restriction.

Authors:  Payam Fallahi; Richard Katz; Ian Toma; Ranyang Li; Jonathan Reiner; Kiersten VanHouten; Larry Carpio; Lorraine Marshall; Yi Lian; Sujata Bupp; Sidney W Fu; Frederick Rickles; David Leitenberg; Yinglei Lai; Babette B Weksler; Frederik Rebling; Zhaoqing Yang; Timothy A McCaffrey
Journal:  Gene       Date:  2013-02-27       Impact factor: 3.688

6.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors:  Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 7.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

Review 8. 

Authors:  C Kneitz; J Atta; H Burkhardt
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

Review 9.  Movement Disorders and Hematologic Diseases.

Authors:  Roshni Abee Patel; Deborah A Hall; Sheila Eichenseer; Meagan Bailey
Journal:  Mov Disord Clin Pract       Date:  2020-12-29

10.  IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome.

Authors:  Laura Scaramucci; Marco Giovannini; Pasquale Niscola; Massimiliano Palombi; Luca Cupelli; Andrea Tendas; Alessio Pio Perrotti; Paolo de Fabritiis
Journal:  Asian J Transfus Sci       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.